Publication | Closed Access
DOPA Potentiation in Ablated Animals and Brain Levels of Biogenic Amines in Intact Animals after Prolyl-leucylglycinamide
73
Citations
0
References
1974
Year
PsychopharmacologyPharmacotherapyExperimental PharmacologySocial SciencesNeuroendocrine MechanismBrain LevelsNeurologyNeurochemistryAnimal PhysiologyBehavioral NeuroscienceBehavioural PharmacologyBehavioral PharmacologyDopa TestNeuropharmacologyDopa PotentiationNervous SystemBehavioral PotentiationPharmacologyDopamineNeurophysiologyAblated AnimalsPhysiologyMouse BrainNeuroscienceBiological PsychiatryMedicineNeuropeptides
Prolyl-leucylglycinamide (PLG) wasfound to augment the behavioral effects of DOPA and pargyline in mice and rats when administered orally. Behavioral studies in the DOPA test with repeated doses of PLG over 5 days did not reveal either cumulative or tolerance effects. Ablation of the pituitary, adrenals, ovaries, testes, pineal, spleen, thyroid, parathyroid, one kidney, or thymus did not disrupt this behavioral potentiation of DOPA by PLG. Furthermore, a neurochemical study in mice and rats did not show any significant increase in the content of dopamine, norepinephrine, or serotonin in the mouse brain. These studies suggest that PLG may have direct stimulatory effects on the mouse brain which do not require the presence of a number of somatic organs.